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Effects of Parathyroid Hormone and Alendronate Alone 
or in Combination in Osteoporosis
 
to the editor: 
 
Both Black et al.
 
1
 
 and Finkelstein et
al.
 
2
 
 (Sept. 25 issue) measured markers of bone turn-
over, but neither group took osteoprotegerin into
consideration as a possibly relevant player in bone
remodeling. Osteoprotegerin, a secreted member of
the family of tumor necrosis factor receptors, is a
potent inhibitor of osteoclast activation and differ-
entiation.
 
3,4
 
 In patients with osteoporosis, osteo-
protegerin has been found to correlate strongly with
markers of bone turnover
 
5 
 
— a finding that may
point toward a higher level of osteoprotegerin ex-
pression in patients with a higher level of these
markers.
In limited experimental settings, the serum os-
teoprotegerin level has been found to be increased in
Paget’s disease and to be decreased after treatment
with tiludronate, a common bisphosphonate.
 
6
 
 Os-
teoprotegerin and receptor activator of nuclear fac-
tor-
 
k
 
B (RANK) have been identified as important
determinants of increased bone resorption induced
by estrogen deficiency.
 
7
 
 Taking these relevant find-
ings into consideration, we suspect that there is a
potential interaction among bone mineral density,
changes in the serum alkaline phosphate level, oth-
er possible markers of bone turnover, and the serum
level of osteoprotegerin — an interaction that per-
haps should be considered in further studies on this
issue.
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to the editor: 
 
Bone resorption and bone forma-
tion are coupled, and alendronate, which decreases
bone turnover, impairs the anabolic effect of para-
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thyroid hormone, which increases bone turnover.
 
1-3
 
Thus, combination therapy with the use of a drug
that does not affect bone turnover might be a good
choice. The serum vitamin K level decreases as a
person gets older, and undercarboxylated osteocal-
cin is a marker of skeletal fragility in elderly persons.
Vitamin K has been approved for the treatment of
osteoporosis in Japan and has been reported to re-
duce the risk of vertebral and hip fracture without
changing bone turnover or increasing bone mineral
density. Although the mechanisms remain unclear,
this vitamin might improve bone material proper-
ties by promoting the incorporation of osteocalcin
into bone
 
4
 
 or might induce increases in bone size by
increasing periosteal bone formation.
 
5
 
 Because of
the limited efficacy of drugs and their potential tox-
icity, combination therapy with drugs that have dif-
ferent mechanisms of action is considered to reduce
the risk of fracture. Vitamin K has a very wide safety
range, and we propose combination therapy with
the use of vitamin K as an essential supplement for
the management of osteoporosis.
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to the editor: 
 
Black et al. and Finkelstein et al.,
as well as Khosla, in an accompanying editorial,
 
1
 
suggest that combining parathyroid hormone with
bisphosphonates is a bad idea. I believe that this
suggestion is premature. Neither Black et al. nor
Finkelstein et al. tested the currently approved re-
combinant human parathyroid hormone (1–34),
and neither present any fracture or biopsy data. Spi-
nal bone mineral density increased to a similar ex-
tent with parathyroid hormone and combination
therapy in the study by Black et al. and increased
an impressive 14.8 percent (at the posteroanterior
spine) with combination therapy in the study by
Finkelstein et al. The total-hip bone mineral densi-
ty, as measured by dual-energy x-ray absorptiometry,
increased to a similar or greater extent with combi-
nation therapy. The meaning of data obtained from
quantitative computed tomography (CT) with re-
gard to reduction of the risk of fracture is unclear.
Parathyroid hormone–mediated decreases in fore-
arm bone mineral density are due to increases in
bone area.
 
2
 
Bisphosphonates reduce the risk of hip frac-
tures. It is unknown whether parathyroid hormone
reduces the risk of hip fractures. The clinical mean-
ing of the inhibition of parathyroid hormone–
mediated increases in bone-formation markers by
alendronate is also unknown. Markers of bone for-
mation reflect osteoblast activity, not necessarily
bone formation.
 
3
 
 Additional evidence that we do
not understand the meaning of the biomarker
changes is the observation made by Finkelstein et
al. that after 12 months of parathyroid hormone
administration, levels of bone-formation markers
decline, yet bone mineral density continues to im-
prove. It is too soon to make judgments about para-
thyroid hormone–bisphosphonate combinations
from the available data.
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to the editor: 
 
Since osteoporosis is correlated
with serum 25-hydroxyvitamin D status, analyses of
treatments must take this measurement into ac-
count, both at base line and throughout a study.
Black et al. mention only that their subjects took a
daily multivitamin containing 400 IU of vitamin D.
The subjects in the study by Finkelstein et al. also
took a multivitamin, and 25-hydroxyvitamin D was
measured at base line. Although other values were
measured at six-month intervals, the serum level of
25-hydroxyvitamin D was not. Given that the serum
25-hydroxyvitamin D level is the best measurement
of a person’s vitamin D status, and given the im-
portance of adequate levels of vitamin D to bone
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health,
 
1
 
 it would be appropriate for all studies of
bone metabolism to include measurements of se-
rum 25-hydroxyvitamin D at base line, during the
study, and at its conclusion. Attempting to deter-
mine the efficacy of treatment options related to
osteoporosis without also taking into account con-
current serum 25-hydroxyvitamin D status is prob-
lematic.
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dr. black and colleagues reply: 
 
Dr. Miller makes
some interesting points regarding our study of para-
thyroid hormone and alendronate, although we cer-
tainly do not suggest in our article that combination
therapy with parathyroid hormone and bisphospho-
nate is a bad idea. In fact, we discuss virtually all the
limitations mentioned by Dr. Miller. As he states,
combination therapy does increase bone mineral
density, and this increase was more evident in the
two-year study by Finkelstein et al. than in our one-
year study. However, we hypothesized that the com-
bination would have an additive or synergistic effect,
and in neither study was there evidence that the
combination was superior to the better of the two
agents given alone. There is obviously a great need
for more data with regard both to recombinant
human parathyroid hormone (1–34) (teriparatide),
which was used by Finkelstein et al., and to the full-
length molecule, recombinant human parathyroid
hormone (1–84), which we used. However, the re-
sults of these two studies, along with data present-
ed at the September 2003 meeting of the American
Society for Bone and Mineral Research, suggest that
parathyroid hormone (1–84) and parathyroid hor-
mone (1–34) interact with alendronate in similar
ways. As we discuss in our article, the results with
alendronate cannot necessarily be generalized to
combination therapy with other bisphosphonates
or other antiresorptive drugs. The implications of
quantitative CT and biochemical-marker end points
with respect to bone strength and the risk of frac-
ture are not entirely clear, and final judgment awaits
more definitive trials. However, with that caveat,
we believe that the data that are currently available
support the notion that responses to parathyroid
hormone therapy are maximized when bone turn-
over is not being suppressed during the course of
treatment.
In response to Dr. Sugiyama and colleagues: Al-
though our study did not provide evidence of a syn-
ergistic effect of parathyroid hormone and alendro-
nate, it is entirely possible that other combinations
of anabolic and antiresorptive agents would have
other results. In addition, other combinations, in-
cluding combinations with vitamin K, might be use-
ful to study.
In response to Dr. Vegni and colleagues: Osteo-
protegerin is a potentially useful surrogate marker
that might provide distinct information. We agree
that it should be included in future studies.
In response to Dr. Fuller: Our patients had suffi-
cient vitamin D levels, according to measurements
made at base line. Because their dietary intake of vi-
tamin D was supplemented with 400 IU daily (as rec-
ommended by the Food and Drug Administration),
it is highly unlikely that our patients became vitamin
D–deficient during the study. We agree that this nu-
trient is important in therapeutic regimens for os-
teoporosis. We look forward to seeing analyses
(from our own study and others) of the effect of
base-line vitamin D levels on the effect of parathy-
roid hormone.
 
Dennis M. Black, Ph.D.
 
University of California, San Francisco 
San Francisco, CA 94109
dblack@psg.ucsf.edu
 
John Bilezikian, M.D.
 
Columbia University
New York, NY 10032
 
Clifford J. Rosen, M.D.
 
Maine Center for Osteoporosis Research and Education
Bangor, ME 04401
 
for the PaTH (Parathyroid Hormone 
and Alendronate) Study Investigators
 
dr. finkelstein and colleagues reply: 
 
Dr. Vegni
and colleagues note the importance of osteoprote-
gerin as an inhibitor of osteoclastic bone resorption.
Although the meaning of circulating osteoproteger-
in levels is still unclear, we are measuring serum os-
teoprotegerin levels in stored samples from our pa-
tients and will analyze these data.
Dr. Sugiyama and colleagues suggest that com-
bining vitamin K with parathyroid hormone might
be useful in the treatment of osteoporosis. Random-
ized, controlled clinical trials are needed to test this
interesting idea.
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Dr. Miller notes that we did not use the currently
approved formulation of recombinant human para-
thyroid hormone (1–34). Our formulation of hu-
man parathyroid hormone (1–34), made by solid-
phase synthesis, is identical to the recombinant
molecule and produces results indistinguishable
from those obtained with the recombinant molecule
in animals and humans. Dr. Miller also notes that
we did not report the incidence of fracture and can-
not be certain how the observed changes in bone
density and bone turnover will affect the risk of frac-
ture. For that reason, we were careful to state in our
conclusions that “additional studies are needed be-
fore combinations of antiresorptive agents and
parathyroid hormone can be recommended for the
treatment of men with osteoporosis.” As Dr. Miller
notes, combination therapy was associated with an
impressive increase in spinal bone mineral density.
Parathyroid hormone monotherapy was even better,
however. In laboratory animals, there is a direct re-
lationship between parathyroid hormone–induced
increases in bone mineral density and resistance to
fracture. Considerable evidence also demonstrates a
direct relationship between increases in bone min-
eral density and decreases in the risk of fracture in
humans.
 
1
 
 Thus, until clinical trials compare the ef-
fects of parathyroid hormone alone and those of
parathyroid hormone plus alendronate on the risk
of fracture, it seems reasonable to treat patients with
the regimen that provides greater increases in bone
density, particularly because parathyroid hormone
monotherapy is less expensive than combination
therapy and exposes patients to a lower risk of side
effects.
Dr. Fuller is concerned that only base-line levels
of 25-hydroxyvitamin D are reported, and that the
results might have been altered if the subjects sub-
sequently had vitamin D deficiency. Although we did
not report these data, we did measure serum 25-
hydroxyvitamin D levels every six months. The mean
(
 
±
 
SD) levels ranged from a low of 23
 
±
 
8 ng per mil-
liliter to a high of 25
 
±
 
9 ng per milliliter in the men
treated with alendronate alone, from 18
 
±
 
5 to 27
 
±
 
10
ng per milliliter in the men treated with parathyroid
hormone alone, and from 21
 
±
 
7 to 28
 
±
 
12 ng per
milliliter in the men treated with both. These levels
did not differ significantly among the groups.
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-Dimer in Venous Thromboembolism
 
to the editor: 
 
Wells and colleagues (Sept. 25 is-
sue)
 
1
 
 report on the use of 
 
d
 
-dimer testing in patients
with suspected deep-vein thrombosis. Patients with
a low pretest probability of deep-vein thrombosis
and a negative result on the 
 
d
 
-dimer test did not
undergo confirmatory testing. This is problematic.
Current recommendations for the evaluation of new
diagnostic tests suggest an independent, blinded
comparison with a reference standard and applica-
tion of that standard independently of the test being
evaluated.
 
2
 
 The gold standard for deep-vein throm-
bosis is either duplex ultrasonography or venogra-
phy, neither of which was performed in this study
group. The “gold standard” for these patients was
the absence of a clinical event at three months. A
false negative result would be identified if a patient
had a symptomatic recurrence. It is unclear whether
there would be a significant number of such recur-
rences in just three months. These limitations make
it likely that the study overestimates the sensitivity
and clinical utility of 
 
d
 
-dimer testing. In addition,
other studies have suggested that the SimpliRED
assay has only 77 percent sensitivity for detecting
pulmonary embolism.
 
3
 
 Confirmation of the utility
of 
 
d
 
-dimer testing awaits trials that uniformly ap-
ply diagnostic standards.
 
Scott D. Stern, M.D.
 
University of Chicago
Chicago, IL 60637
 
1.
 
Wells PS, Anderson DR, Rodger M, et al. Evaluation of 
 
d
 
-dimer
in the diagnosis of suspected deep-vein thrombosis. N Engl J Med
2003;349:1227-35.
 
2.
 
Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical
literature. III. How to use an article about a diagnostic test. B. What
are the results and will they help me in caring for my patients. JAMA
1994;271:703-7.
 
3.
 
Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary
embolism at the bedside without diagnostic imaging: management
of patients with suspected pulmonary embolism presenting to the
emergency department by using a simple clinical model and 
 
d
 
-dimer.
Ann Intern Med 2001;135:98-107.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 